论文部分内容阅读
脂蛋白(a)[lipoprotein(a),Lp(a)]是一种独立的脂蛋白颗粒,由肝脏合成的载脂蛋白(a)[Apolipoprotein(a),Apo(a)]分泌至循环中与LDL结合所形成。血液中的Lp(a)浓度不受性别、年龄、饮食、理化等因素及多种降脂药物的影响,是一种稳定的遗传学标志。血清Lp(a)与糖尿病肾病(diabetic nephropathy,DN)关系密切,DN患者血清Lp(a)水平显著增高,且与尿微量白蛋白排泄率(UAER)呈正相关,Lp(a)又可通过多种机理对肾脏造成损伤。在糖尿病病人中进行血清Lp(a)的监测有可能作为一种反应早期肾损伤的辅助指标应用于临床。但因其特异性差,其他肾病、心血管疾病、脂代谢紊乱性疾病及急性炎症时均可升高,需要进一步的基础和临床研究探讨。
Lipoprotein (a), a lipoprotein (a), is an isolated lipoprotein particle secreted by the liver into the circulation by apolipoprotein (a) [Apo (a)] Formed with LDL binding. Blood Lp (a) concentration is not gender, age, diet, physical and chemical and other factors and a variety of lipid-lowering drugs, is a stable genetic markers. Serum Lp (a) is closely related to diabetic nephropathy (DN). Serum Lp (a) level is significantly increased in DN patients and positively correlated with urinary albumin excretion rate (UAER). Lp (a) The mechanism causes damage to the kidneys. The monitoring of serum Lp (a) in diabetic patients may be used clinically as an adjunct to early renal damage. However, due to its poor specificity, other kidney diseases, cardiovascular diseases, disorders of lipid metabolism and acute inflammation can be elevated, the need for further basic and clinical research.